Trial reportThrombosis and haemostasis2018
Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study).
Trial report in Thrombosis and haemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03568838 (Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention Compared With Standard of Care Therapy - The PENNYWISE Feasibility Study), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention Compared With Standard of Care Therapy - The PENNYWISE Feasibility Study
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Safety and efficacy of routine anticoagulation after primary PCI in STEMI: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study.Thrombosis and haemostasis · 2020Trial
- AQUATIC findings sink antiplatelet therapy for patients with chronic coronary syndrome requiring oral anticoagulants.Nature reviews. Cardiology · 2025Article
- Bibliometric analysis of the no-reflow in ST-segment elevation myocardial infarction patients post-percutaneous coronary intervention: unveiling research trends, collaborative networks, and therapies.Journal of thoracic disease · 2025Article
- Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction.Biomedicines · 2024Review
- Defective recovery of QT dispersion due to no-reflow following acute interventional therapy in patients with ST-segment elevation myocardial infarction.Cardiovascular diagnosis and therapy · 2024Article
- Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review.Pharmacogenomics and personalized medicine · 2023Review
- Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2022Review
- New Antithrombotic Drugs in Acute Coronary Syndrome.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
Delayed onset of action of oral P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.